Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19

Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19 February 19, 2021 Corporate News Marinomed Biotech AG (VSE:MARI) announces that a nasal spray with iota -carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with t his disease. These were the results of an independent and investigator -initiated study (IIT; CARR -COV-02, NCT04521322) conducted by an Argentinian research group. In the multicenter, randomized, double-blind, controlled CARR-COV-02 study, 394 healthcare staff were randomly assigned to receive iota-carrageenan nasal spray (N = 199) or placebo (N = 195) four times per day. Both groups had similar gender and age distributions. The percentage of participants that developed COVID-19 was significantly lower in the group that received the iota -carrageenan spray compared to placebo (1.0% vs 5.1%, respectively; relative risk reduction for disease of 80.4 %; 95 % CI = 25 -95 % - there is a 95 % chance that the risk reduction is in this range). The difference betwee n the groups were statistically significant (Chi square test p = 0.01). Iota-carrageenan nasal spray was safe and well tolerated, and minor side effects, such as postnasal drip, were observed with a similar frequency in both groups (2.0 %). The investi gator-initiated CARR -COV-02 study (NCT04521322) was conducted by an Argentinian research group represented by Dr. Juan M. Figueroa, Institute of Science and Technology Cesar Milstein-Hospital de Clínicas-UBA; Dr. Mónica Lombardo, Nobeltri SRL and Hospital Universitario CEMIC; Dr. Ariel Dogliotti, Rosario Cardiovascular Institute; Dr. Luis P. Flynn, Sanatorium of Children of Rosario; Dr. Osvaldo Uchitel, Institute of Physiology, Molecular Biology and Neurosciences UBA-CONICET. The data have been publishe d on the website of the Instituto de Ciencia y Tecnología César Milstein: https://milstein.conicet.gov.ar/la-eficacia-del-spray-nasal-con-carragenina-para-la- prevencion-del-covid-19-ha-dado-resultados-positivos/ Dr. Andreas Grassauer, CEO of Marinomed, said: “The positive results of this important clinical trial with caregivers and hospital staff, highly exposed to infection risks, are confirming earlier findings on the antiviral activity of Carragelose against SARS -CoV-2. For the first time, the potential of Carragelose for the prevention of COVID -19 was demonstrated in a co ntrolled clinical setting. As a next step, Marinomed is now planning clinical tests using the same technology for an inhalation solution that could treat pulmonary viral infections. The trial will include patients at risk for virally induced pneumonia, a m ain complication of COVID-19 and other viruses, such as Influenza A.” Carragelose coats the mucosal tissues of the respiratory tract, forming a physical barrier that helps to protect against viral infection and viral spread. This in turn has been shown to reduce the viral load, and the body’s own natural defense may fight the virus more efficiently. The new results from this independent clinical trial in Argentina show that this mechanism of action also works against SARS-CoV-2, as already demonstrated in multiple preclinical studies by Marinomed and others. A particular advantage of Carragelose is the broad activity of the polymer against different virus strains, such as Rhinovirus and already known endemic Coronaviruses. This effectiveness of Carra gelose has been proven in earlier clinical trials with more than 600 patients suffering from early symptoms of the common cold. In addition, the safety profile of Carragelose is excellent. Products containing Carragelose, such as nasal sprays, lozenges or a throat spray have been marketed in Austria since 2008. By now, the products have been established as the first causative treatment of common cold and flu -like diseases worldwide and are distributed in more than 40 countries. About Carragelose®: Carragelose® is a sulfated polymer from red seaweed and a unique, broadly active anti -viral compound. It is known as a gentle yet effective and safe prevention and treatment against respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a layer on the mucosa wrapping entering viruses, thereby inactivating them, and preventing them from infecting cells. On February 18, 2021, the Company has informed that a recent study conducted by the Institute of Virology, Friedr ich-Alexander University Erlangen-Nuremberg, Germany and Marinomed confirms previous studies showing efficacy of Carragelose® in preventing SARS -CoV-2 infection in vitro. Marinomed is holder of the IP rights and has licensed Carragelose® for marketing in E urope, parts of Asia, Canada, and Australia. For a full list of Marinomed’s portfolio of Carragelose®-containing nasal sprays and oral products, please visit https://www.carragelose.com/en/portfolio/launched -products, for a list of scientific publications on Carragelose®, https://www.carragelose.com/en/publications. About Marinomed Biotech AG Marinomed Biotech AG (Korneuburg, Austria) is a biopharmaceutical company listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the deve lopment of innovative products based on two patent -protected technology platforms. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS -CoV-2. Carragelose® is used in nasal sprays, throat sprays and lozenges, whi ch are sold via international partners in over 40 countries worldwide. Marinomed, Marinosolv® und Carragelose® are registered trademarks of Marinomed AG. These trademarks may be owned or licensed in select locations only. Further information is available a t https://www.marinomed.com/en/technologies - markets/markets. For further inquiries contact: Dr. Eva Prieschl-Grassauer Chief Scientific Officer, Marinomed Hovengasse 25, 2100 Korneuburg, Austria T +43 2262 90300 E-mail: [email protected] https://www.marinomed.com/en/ International Media Contact MC Services AG Dr. Brigitte Keller, Julia Hofmann T +49 89 210228 0 UK: Shaun Brown M: +44 7867 515 918 E-mail: [email protected] Media Contact Austria Metrum Communications GmbH Roland Mayrl T +43 1 5046987-331 E-Mail: [email protected] Disclaimer This press release contains forward -looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be id entified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not as sume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.

The release as fetched from its publisher. marinomed.com ↗